Clinical Scorecard: Utilizing Bacillus Calmette-Guérin as an Adjuvant to Boost the Immunogenic Response to Conserved Epitopes from SARS-CoV-2 Structural Proteins

At a Glance

Key Highlights

• Conserved epitopes from structural proteins E, M, N, and S are promising vaccine targets.
• BCG enhances immunogenicity of SARS-CoV-2 peptides, inducing trained immunity.
• In vivo studies show increased cytokine production and memory responses in vaccinated mice.
• In silico modeling indicates stable and non-allergenic multiepitope constructs.

Guideline-Based Recommendations

Diagnosis

• Utilize serological assays to confirm SARS-CoV-2 infection status.

Management

• Consider BCG as an adjuvant in vaccine formulations targeting conserved SARS-CoV-2 epitopes.

Monitoring & Follow-up

• Monitor immune responses through cytokine profiling and antibody titers post-vaccination.

Risks

• Evaluate potential adverse effects of BCG in immunocompromised populations.

Patient & Prescribing Data

Patients with a history of COVID-19 or at high risk for severe disease.

BCG may enhance the efficacy of vaccines targeting conserved SARS-CoV-2 epitopes.

Clinical Best Practices

• Incorporate BCG in vaccine strategies to improve immune responses against SARS-CoV-2.
• Utilize a combination of in vitro and in vivo studies to validate vaccine efficacy.

Related Resources & Content

• Study on BCG and SARS-CoV-2